It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

US stocks were mixed Thursday morning as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...